Heron Therapeutics (HRTX) CFO Ira Duarte Exercises RSUs; Shares Withheld

What Happened

• Ira Duarte, Chief Financial Officer of Heron Therapeutics (HRTX), had restricted stock units (RSUs) convert to common shares on July 30–31, 2026. A total of 25,229 RSUs vested/converted into shares (13,535 on 7/30 and 11,694 on 7/31). To satisfy tax withholding, Duarte had 3,850 shares withheld on 7/30 and 3,326 shares withheld on 7/31 at $0.50 per share, totaling 7,176 shares withheld and $3,588 paid for taxes. Net shares delivered to Duarte after withholding: 18,053 shares.

Key Details

• Transaction dates: July 30, 2026 (13,535 RSUs) and July 31, 2026 (11,694 RSUs).
• Withholding (code F): 3,850 shares @ $0.50 = $1,925 (7/30); 3,326 shares @ $0.50 = $1,663 (7/31); total $3,588.
• Derivative conversion (code M): RSUs converted to common stock; derivative disposition entries show $0.00, reflecting settlement of RSUs (no cash exercise price).
• Footnotes: RSUs = contingent right to one share. These RSUs were part of a Jan 30, 2026 grant of 216,562 RSUs that vest in 16 equal quarterly installments (time-based vesting).
• Filing: Form 4 filed with accession 0001193125-26-329720 on Aug 3, 2026; Period of Report listed as Jul 30, 2026.
• The filing does not specify total shares owned by Duarte after these transactions.

Context

• This report reflects routine RSU vesting and share withholding to cover tax liabilities (a common cashless settlement); it is not an open‑market purchase or sale that necessarily signals a buying or selling preference. The withholding price shown ($0.50) is the per‑share amount used for tax purposes in this settlement and is small relative to market values.